Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta/Smad-induced growth arrest of prostate cells.

Oncogene - 14 Sept 2006

Noda D, Itoh S, Watanabe Y, Inamitsu M, Dennler S, Itoh F, Koike S, Danielpour D, ten Dijke P, Kato M

Abstract excerpt

Transforming growth factor-beta (TGF-beta) elicits a potent growth inhibitory effect on many normal cells by binding to specific serine/threonine kinase receptors and activating specific Smad proteins, which regulate the expression of cell cycle genes, including the p21 cyclin-dependent kinase (CDK) inhibitor gene. Interestingly, cancer cells are often insensitive to the anti-mitogenic effects of TGF-beta for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Division
Share to Chlorocebus aethiops

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COS Cells

Share to Neoplasm Proteins

Share to Prostatic Neoplasms

Share to RNA, Small Interfering

Share to Smad Proteins

Share to Transforming Growth Factor beta

Source

Identifiers

PMID: 16636667
DOI: 10.1038/sj.onc.1209571

Genes

ELAC2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-beta/Smad-induced growth arrest of prostate cells.PMID 16636667Read ↗

The product of the candidate prostate cancer susceptibility gene ELAC2 interacts with the gamma-tubulin complex.Semantic proximity Read ↗

Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2.Semantic proximity Read ↗

FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cellsSemantic proximity Read ↗

CtBP2 modulates the androgen receptor to promote prostate cancer progression.Semantic proximity Read ↗

ELL Protein-associated Factor 2 (EAF2) Inhibits Transforming Growth Factor β Signaling through a Direct Interaction with Smad3Semantic proximity Read ↗

The LATS2/KPM Tumor Suppressor Is a Negative Regulator of the Androgen ReceptorSemantic proximity Read ↗

TACC2 Is an Androgen-Responsive Cell Cycle Regulator Promoting Androgen-Mediated and Castration-Resistant Growth of Prostate CancerSemantic proximity Read ↗

Identification of βArrestin2 as a corepressor of androgen receptor signaling in prostate cancerSemantic proximity Read ↗

CKAP2L, a Crucial Target of miR-326, Promotes Prostate Cancer ProgressionSemantic proximity Read ↗

Novel Androgen Receptor Coregulator GRHL2 Exerts Both Oncogenic and Antimetastatic Functions in Prostate CancerSemantic proximity Read ↗

Increased Expression of SIM2-s Protein Is a Novel Marker of Aggressive Prostate CancerSemantic proximity Read ↗

CLCA2 epigenetic regulation by CTBP1, HDACs, ZEB1, EP300 and miR‐196b‐5p impacts prostate cancer cell adhesion and EMT in metabolic syndrome diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.